Affiliation:
1. Section of Pharmacology and Clinical Pharmacology, Department of Physiology, Pathophysiology and Pharmacology, Faculty of Medicine, Trakia University, Stara Zagora, Bulgaria
Abstract
Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) are oral antidiabetic agents commonly used for the treatment of type 2 diabetes mellitus. More than ten years of clinical experience with this group of drugs provides evidence of their efficacy and good tolerability especially in patients at risk of hypoglycemia. DPP-4 inhibitors act by increasing the levels of the incretins glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) and thus augmenting glucose-induced insulin secretion. The enzyme DPP-4 degrades plenty of substrates including chemokines, cytokines, and neuropeptides. Thus the inhibition of DPP-4 may affect many biological and pathological processes. Although rarely DPP-4 inhibitors have been reported to induce the development of infections, heart failure, liver injury and pancreatitis. The long-term effects of DPP-4 inhibition on the immune function are still not clarified. The close monitoring of polymorbid patients using DPP-4 inhibitors, and the reporting of possible adverse reactions associated with these drugs is warranted.
Reference59 articles.
1. Nathan, D.M., Finding new treatments for diabetes—how many, how fast... How good? NEJM, 356,(5): 437–440, 2007.
2. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Market 2022 to Eyewitness Massive Growth by 2028 https://www.marketwatch.com/press-release/dipeptidyl-peptidase-4-dpp-4-inhibitors-market-2022-to-eyewitness-massive-growth-by-2028-2022-10-21)
3. Nolte Kennedy, M.S. and Masharani, U, Pancreatic Hormones and Antidiabetic Drugs.In: Katzung, B.G. (ed) Basic & Clinical Pharmacology, 14th ed., McGraw-Hill Companies, Inc., pp 747-771, 2018.
4. Doyle, M.E and Egan, J.M., Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther, 113:546-593, 2007.
5. Komatsu, R., Matsuyama, T., Namba, M., Watanabe, N., Itoh, H., Kono, N., Tarui, S., Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7–36)-amide. Diabetes, 38:902-905, 1989.